ライフサイエンスコーパス: hepatic allograft

1 hysiologic phenomenon, adversely affects the hepatic allograft.

2 ibute to the comparative immune privilege of hepatic allografts.

3 ntial use to attenuate the immunogenicity of hepatic allografts.

4 Controlled NHBDs contributed 5% of hepatic allografts (8/164) from August 1996 through June

5 nity, autoimmunity, and in the regulation of hepatic allograft acceptance.

6 e of immune activation were monitored in the hepatic allograft and in the host spleen by analyses of

7 ity of illness, including poorly functioning hepatic allograft and renal failure may be the major det

8 for the treatment of primary nonfunction of hepatic allografts and fulminant hepatic failure.

9 nib-eluting beads (SEBs) in rabbits with VX2 hepatic allografts and to investigate treatment effects

10 tients (70.3%) were alive with their initial hepatic allograft at the conclusion of the study period

11 ient survival among adult recipients of NHBD hepatic allografts compared with recipients of HBD liver

12 ion between donor cardiopulmonary arrest and hepatic allograft dysfunction.

13 Fifteen patients received a hepatic allograft from a controlled NHBD donor.

14 nd 16 anti-HBs-, HbsAg- patients received an hepatic allograft from a donor positive for anti-HBc.

15 Twenty-five of 48 recipients of a hepatic allograft from a donor positive only for anti-HB

16 Twenty-five of 41 naive recipients of a hepatic allograft from an anti-HBc positive donor were s

17 ts positive only for anti-HBc who received a hepatic allograft from an anti-HBc-positive donor were s

18 onor organs occasionally mandates the use of hepatic allografts from anti-HBc+ donors in recipients w

19 infection in anti-HBs-, HbsAg- recipients of hepatic allografts from anti-HBc+ donors.

20 Hepatic allografts from anti-HBc-positive donors frequen

21 Hepatic allografts from donors positive only for anti-HB

22 By contrast, hepatic allografts from donors treated with the hematopo

23 Hepatic allografts from donors who have suffered a brief

24 Recipients of hepatic allografts from donors with antibodies to HBV we

25 Since suitable recipients for hepatic allografts from donors with antibodies to hepati

26 ans, there is renewed interest in the use of hepatic allografts from NHBDs.

27 Hepatic allografts from non-heart-beating donors (NHBD)

28 All surviving patients have normal hepatic allograft function.

29 suggesting PGE1 infusion improves immediate hepatic allograft function.

30 were split in situ and used as reduced-size hepatic allografts in four recipients.

31 Hepatic allograft inflammation grade >/=2 and fibrosis s

32 on tests are elevated in an organ donor, the hepatic allograft is suitable for OLT if the liver damag

33 Preservation-reperfusion injury of hepatic allografts is thought to be associated with Kupf

34 reviews the use of plasmapheresis in primary hepatic allograft nonfunction (PNF).

35 nce of brief donor cardiopulmonary arrest on hepatic allograft outcome in human liver transplantation

36 es from 901 adult tacrolimus-treated primary hepatic allograft recipients between August 1995 and Sep

37 (PBC), graft-versus-host disease (GVHD), and hepatic allograft rejection (HAR), also occurs in the B1

38 Hepatic allograft rejection remains an important problem

39 GST may be useful in the management of early hepatic allograft rejection.

40 markers may be beneficial to diagnose early hepatic allograft rejection.

41 serologic markers in the management of early hepatic allograft rejection.

42 data demonstrate that the failure of primary hepatic allografts remains a major problem in pediatric

43 However, the effect of HLA matching for hepatic allografts remains poorly defined.

44 rest in organ donors did not affect post-OLT hepatic allograft survival and function.

45 The overall hepatic allograft survival rate was equivalent to the ov

46 d the association between HLA mismatches and hepatic allograft survival, disease recurrence, and immu

47 In both the native liver and hepatic allograft, the lymphoma presented as a sparse cy

48 Donor warm ischemic time may predispose hepatic allografts to an increased incidence of ischemic

49 The loss of hepatic allografts to the rejection processes is now rel

50 are homozygous at all HLA loci as donors of hepatic allografts to their children.

51 g evidence that PSC frequently recurs in the hepatic allograft using strict inclusion and exclusion c

52 HBIG can protect against reinfection of the hepatic allograft with the YMDD HBV escape mutant.